medigraphic.com
Colegio de Medicina Interna de México.

2007, Número 1

<< Anterior Siguiente >>

Med Int Mex 2007; 23 (1)


Aproximación práctica a la prescripción de los fármacos antiarrítmicos

Asensio LE, Galindo UJ, Orea TA, Narváez DR, Dorantes GJ, Castillo ML, Rebollar GV, Hernández RP, Oseguera MJ

Idioma: Español
Referencias bibliográficas: 44
Paginas: 59-65
Archivo PDF: 153.51 Kb.


RESUMEN

Las opciones de medicamentos para el tratamiento de las arritmias son variadas, pero a menudo los resultados no son los esperados ni por el médico ni por el paciente. Esto se debe, en muchas ocasiones, a que la elección del fármaco antiarrítmico no necesariamente es la más apropiada. De aquí que en múltiples casos sea válida la pregunta sobre si realmente funcionan estos medicamentos. La finalidad del presente trabajo es proporcionar información útil para seleccionar el agente antiarrítmico más apropiado a una situación determinada.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The CAST investigators. Preliminary report. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.

  2. Epstein A, Bigger T, Wyse G, Romhilt W, et al. Events in the cardiac arrhythmia suppression trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol 1991;18:14-9.

  3. Camm J, Julian D, Janse G. The European Myocardial Infarct Amiodarone Trial (EMIAT). Am J Cardiol 1993;72:95F-98F.

  4. Cairns J, Connolly S, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive premature depolarisations: CAMIAT. Lancet 1997;349:675-82.

  5. Moss A. Bakground, outcome and clinical implications of the multicenter automatic defibrillator implantation trial (MADIT). Am J Cardiol 1997;80(5B):28F-32F.

  6. Gold R. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol 2000;23(11):1981-5.

  7. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. An international consensus on science. The American Heart Association in collaboration with the International Committee on Resuscitation (ILCOR). Circulation 2000;102(suppl):I1-384.

  8. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. An international consensus on science. The American Heart Association in collaboration with the International Committee on Resuscitation (ILCOR). Circulation 2005:112:IV1-211.

  9. Dec G. Digoxin remains useful in the management of chronic heart failure. Med Clin North Am 2003;87(2):317-37.

  10. Lader E, Egan D, Hunsberger S, Grag R, et al. The effect of digoxin on the quality of life in patients with heart failure. J Card Fail 2003;9(1):4-12.

  11. Rich M, McSherry F, Williford W, Yusuf S. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol, 2001;38(3):806-13.

  12. See S, Bruno P. Digoxin increases mortality among women with congestive heart failure. J Fam Pract 2003;52(2):106-11.

  13. Boriani G, Biffi M, Diemberger I, Martignani C, et al. Rate control in atrial fibrillation: choice of treatment and assessment of efficacy. Drugs 2003;63(14):1489-509.

  14. Shibata M, Flather M, Wang D. Systematic review of the impact of beta-blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3(3):351-7.

  15. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001;110 (suppl7A):81S-94S.

  16. Crespo M, Paniagua M. Tratamiento de la insuficiencia cardiaca severa o refractaria. Rev Esp Cardiol 2004;57(9):869-83.

  17. Jafri S. The effects of beta-blockers on morbidity and mortality in heart failure. Heart Fail Rev 2004;9(2):115-21.

  18. Vaughan-Williams E. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47.

  19. Task force of the Working Group on Arrhythmias of the European Society of Cardiology: the Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-51.

  20. Members of the Sicilian Gambit new approaches to antiarrhythmic therapy. Emerging therapeutic applications of the cell biology of cardiac arrhythmias. Eur Heart J 2001;(22):2148-63.

  21. Fogoros R. Electrophysiologic testing. 2nd ed. Toronto: Blackwell Science, 1995.

  22. Langan M. The impact of recent ion channel science on the development and use of antiarrhythmic drugs. Curr Cardiol Rep 1999;1(4):302-7.

  23. Katz A. The cardiac action potential. In: Katz A. editor. Physiology of the heart, 3rd ed. Chicago: Lippincott Williams and Wilkins, 2001;pp:478-516.

  24. Ogawa S. Differences in selection criteria for antiarrhythmic drugs in Japan and the US. Intern Med 2004;43(2):161-2.

  25. Sanguinetti M, Bennett P. Antiarrhythmic drug target choices and screening. Circ Res 2003;93(6):491-9.

  26. Peters N, Cabo C, Wit A. Arrhythmogenic mechanisms: automaticity, triggered activity and reentry. In: Zipes D, Jalife J. editors. Cardiac electrophysiology. From cell to bedside. 3rd ed. Philadelphia: W.B. Saunders, 2000;pp:345-55.

  27. Marcus F, Opie L. Agentes antiarrítmicos. En: Opie L. editor. Fármacos en cardiología. 4ª ed. México: McGraw-Hill Interamericana, 1995;pp:223-66.

  28. Podrid P. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995;122(9):689-700.

  29. Freedman M, Somberg J. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 1991;31(11):1061-9.

  30. Yin Y, Perret G, Nicolas P, Vassy R, et al. In vivo effects of amiodarone on beta-adrenoceptor density and heart rate require thyroid hormones. J Cardiovasc Pharmacol 1992;19(4):541-5.

  31. Lubic S, Nguyen K, Dave B, Giacomini J. Antiarrhythmic agent amiodarone possesses calcium channel blocker properties. J Cardiovasc Pharmacol 1994;24(5):707-14.

  32. Burckhardt D. Clinical efficacy of long term treatment with amiodarone for life-threatening arrhythmias. J Cardiovasc Pharmacol 1992;20(suppl2):S59-62.

  33. Asensio E, Álvarez B, Lozano E, Farías A, et al. Bloqueo de rama derecha, elevación del ST y muerte súbita: síndrome de Brugada. Arch Inst Cardiol Mex 2000;70(3):301-11.

  34. Stelfox H, Ahmed S, Fiskio J, Bates D. Monitoring amiodarone’s toxicities: recommendations, evidence and clinical practice. Clin Pharmacol Ther 2004;75(1):110-22.

  35. Ott M, Khoor A, Leventhal J, Paterick T, et al. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003;123(2):646-51.

  36. Barbey J. Clinical pharmacology and beta-blocking efficacy of propafenone. J Cardiovasc Pharmacol 1991;17(suppl6):S41-3.

  37. Koller B, Franz M. New classification of moricizine and propafenone based on electrophysiologic and electrocardiographic data from isolated rabbit heart. J Cardiovasc Pharmacol 1994;24(5):753-60.

  38. Zaza A, Malfatto G, Schwartz P. Diverse electrophysiologic effects of propafenone and flecainide in canine purkinje fibres: implications for antiarrhythmic drug classification. J Pharmacol Exp Ther 1994;269(1):336-43.

  39. Tamargo J. Propafenone slows conduction and produces nonuniform recovery of excitability between purkinje and ventricular muscle fibers. J Cardiovasc Pharmacol 1993;22(2):203-7.

  40. Naccarelli G, Wolbrette D, Khan M, Bhatta L, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003;91(6A):15D-26D.

  41. Kidwell G, González M. Effects of flecainide and D-sotalol on myocardial conduction and refrasctoriness: relation to antiarrhythmic and proarrhythmic drug effects. J Cardiovasc Pharmacol 1993;21(4):621-32.

  42. Nitta J, Sunami A, Maruno F, Hiraoka M. States and sites of action of flecainide on guinea-pig cardiac sodium channels. Eur J Pharmacol 1992;214(2-3):191-7.

  43. Boriani G, Capucci A, Strocchi E. Calliva R, et al. Flecainide acetate: concentration response relationships for antiarrhythmic and electrocardiographic effects. Int J Clin Pharmacol Res 1993;13(4):211-9.

  44. Opie L, Sonnenblick-Frishman W, Thadani U. Agentes de bloqueo beta. En: Opie L, editor. Fármacos en cardiología. 4ª ed. México: McGraw-Hill Interamericana, 1995;pp:1-32.




2020     |     www.medigraphic.com